Addyi FDA Approval History: How Flibanserin Got to Market

What Is Flibanserin and Why Does Its Regulatory Path Matter?

Flibanserin is a small-molecule, non-hormonal drug that acts as a 5-HT1A agonist and 5-HT2A antagonist in the central nervous system. It was developed to address hypoactive sexual desire disorder (HSDD), a condition characterized by persistent low sexual desire that causes personal distress and is not explained by another psychiatric condition or relationship problem. The American Psychiatric Association's DSM-5 formally recognizes this presentation as Female Sexual Interest/Arousal Disorder.

HSDD affects an estimated 8 to 10 percent of premenopausal women in the United States when distress criteria are applied, according to epidemiological data published in Obstetrics and Gynecology. Before flibanserin, no FDA-approved pharmacological option existed for this population. That gap gave the regulatory path outsized clinical and commercial significance: every FDA advisory committee vote and every Complete Response Letter was watched closely by patients, advocates, and clinicians who had been prescribing off-label options for years.

Why the Mechanism Is Different from Hormonal Therapies

Flibanserin does not alter estrogen, testosterone, or any other sex hormone. Its target is the serotonin system. By acting as a partial agonist at 5-HT1A receptors and an antagonist at 5-HT2A receptors, the drug is thought to increase dopamine and norepinephrine release in the prefrontal cortex while reducing serotonin activity in that same region. The net effect, in theory, is a shift in neurochemical tone that favors sexual motivation.

This mechanism also explains the drug's central side-effect profile, specifically somnolence, dizziness, and the dangerous interaction with alcohol and certain CYP3A4 inhibitors.

The Two FDA Rejections: 2010 and 2013

Flibanserin's road to approval is one of the more extensively documented regulatory stories in recent FDA history. Boehringer Ingelheim first submitted a New Drug Application (NDA) for flibanserin in 2010. The FDA convened an advisory committee in June 2010, and the panel voted 10 to 1 against approval. The agency issued a Complete Response Letter the same month.

The 2010 Rejection: Efficacy Concerns

The 2010 CRL centered on benefit-risk. The advisory committee concluded that the magnitude of efficacy was too small to justify the drug's CNS side effects. In the trials reviewed at that time, active treatment produced approximately 0.7 additional satisfying sexual events (SSEs) per month over placebo. The committee found that improvement statistically significant but clinically questionable, particularly given somnolence rates exceeding 20 percent in treated patients. FDA documents from the 2010 advisory committee meeting reflect this reasoning in full.

The 2013 Rejection: Safety and Study Design

Boehringer Ingelheim sold the flibanserin program to Sprout Pharmaceuticals in 2011. Sprout resubmitted the NDA with additional data. The FDA declined again in December 2013, issuing a second Complete Response Letter that requested further studies quantifying the drug's interaction with alcohol and with CYP3A4 inhibitors, as well as additional data on driving impairment. The agency's concern was not merely statistical: syncope events in the existing safety database were rare but potentially dangerous, and they clustered with concomitant alcohol or CNS-depressant use.

The Road to 2015 Approval

Between 2013 and 2015, Sprout Pharmaceuticals conducted the dedicated alcohol interaction study that the FDA had requested. That study enrolled both men and women and evaluated the hemodynamic effects of flibanserin 100 mg combined with varying amounts of alcohol. The study found that co-administration produced mean nadir systolic blood pressure drops below 80 mmHg in some subjects, a clinically meaningful finding that would shape the final label's black-box warning.

Sprout also engaged in a sustained advocacy campaign. The organization Even the Score argued that the FDA held female sexual dysfunction drugs to a higher standard than male sexual dysfunction drugs, comparing the available treatment options for erectile dysfunction (multiple approved PDE5 inhibitors) with the zero options then available for HSDD. The FDA acknowledged this advocacy in its public communications but maintained that approval decisions are made on individual benefit-risk grounds.

The 2015 Advisory Committee Vote

The FDA's Reproductive Health Drugs Advisory Committee met on June 4, 2015. After reviewing three Phase 3 trials (BEGONIA, SNOWDROP, and VIOLET) and the new alcohol-interaction data, the panel voted 18 to 6 in favor of approval, with the explicit condition that a REMS program be implemented. The committee acknowledged the modest effect size but agreed that premenopausal women with HSDD had no approved treatment alternative and that the benefit was real, provided alcohol was strictly avoided.

Key Trial Data: BEGONIA

The BEGONIA trial (NCT01057901), published in the Journal of Sexual Medicine in 2014, enrolled 1,378 premenopausal women with HSDD and randomized them to flibanserin 100 mg at bedtime or placebo for 24 weeks. The primary endpoints were the number of satisfying sexual events and the Female Sexual Function Index desire domain score. Flibanserin-treated women reported a mean increase of 2.5 SSEs per month from a baseline of approximately 2.7, compared with 1.5 SSEs per month in the placebo group, a difference of approximately 1.0 SSE per month (P<0.001). BEGONIA trial publication in J Sex Med [1]. Distress scores on the Female Sexual Distress Scale-Desire/Arousal/Orgasm also improved significantly in the active arm.

The pooled analysis across BEGONIA, SNOWDROP, and VIOLET, covering more than 5,000 women, consistently showed active drug superiority over placebo on both co-primary endpoints, though effect sizes remained in the range of 0.5 to 1.0 additional SSE per month. That modest absolute gain, set against a background rate of roughly 2 to 3 SSEs per month at baseline, represents a 30 to 50 percent relative increase in frequency for many participants.

FDA Approval: August 18, 2015

The FDA approved flibanserin 100 mg (Addyi) on August 18, 2015, under NDA 022526. The FDA approval press release described the decision as providing "women with distressing low sexual desire a safe and effective treatment option." The agency's acting chief scientist at the time, Dr. Patrizia Cavazzoni, noted that the approval reflected a careful evaluation of data from more than 11,000 patient-months of exposure in the clinical development program.

Approval was limited to premenopausal women. Postmenopausal women and men were explicitly excluded from the indication because the efficacy database did not include those populations in adequate numbers.

The REMS Program at Launch

Approval came with a Risk Evaluation and Mitigation Strategy, one of the stricter REMS programs the FDA had imposed on a non-opioid medication at that time. The REMS required:

• Prescriber certification: Clinicians must complete training on the alcohol interaction and agree to counsel patients before prescribing.
• Pharmacy certification: Dispensing pharmacies must be enrolled and must confirm patient enrollment.
• Patient enrollment: Each patient must sign a Patient-Provider Agreement Form acknowledging she understands the alcohol prohibition and CNS-depressant risks.

The REMS did not require inpatient initiation or any monitoring procedure, distinguishing it from REMS programs for drugs such as clozapine or sodium oxybate.

The Current Addyi Label: Key Provisions

The current Addyi prescribing information carries a black-box warning, the FDA's strongest alert, covering hypotension and syncope from alcohol interaction.

Black-Box Warning Text

The label states: "Alcohol is contraindicated with Addyi because the combined use of Addyi and alcohol significantly increases the risk of severe hypotension and syncope." This language was refined following the 2019 REMS modification (discussed below), but the contraindication itself has been present since initial approval.

Dosing and Administration

The approved regimen is flibanserin 100 mg taken orally once daily at bedtime. Bedtime dosing was selected to reduce the functional impact of somnolence and dizziness, both of which are dose-dependent CNS effects. The label specifies that treatment should be discontinued after 8 weeks if the patient does not report improvement in symptoms, because continued exposure without benefit does not alter the risk profile favorably.

Patients who miss a dose should skip that dose entirely and take the next scheduled bedtime dose. Taking a missed dose during waking hours is explicitly discouraged because daytime somnolence and hypotension risk increase substantially.

Contraindications

Beyond alcohol, the label contraindicates flibanserin with:

• Moderate or strong CYP3A4 inhibitors (fluconazole, ketoconazole, clarithromycin, and multiple others), which can raise flibanserin plasma concentrations by three- to sixfold
• Moderate or severe hepatic impairment
• Any current use of strong CYP2C19 inhibitors combined with CYP3A4 inhibitors

Common Adverse Effects

Somnolence (11.4 percent of treated patients vs. 3.2 percent placebo), dizziness (11.4 vs. 2.3 percent), nausea (10.4 vs. 3.9 percent), and fatigue (9.2 vs. 5.5 percent) are the most frequently reported adverse effects from the pooled Phase 3 database as listed in the approved label.

The 2019 REMS Modification

In April 2019, the FDA modified the Addyi REMS program following a post-approval pharmacokinetic study that Sprout submitted to address questions about the magnitude of the alcohol interaction under more controlled conditions. The revised study, which used lower and more typical social-drinking alcohol quantities than the original interaction study, found that the risk of severe hypotension was primarily associated with consuming alcohol within two hours before or after taking flibanserin, rather than representing a uniform 24-hour prohibition.

The FDA responded by revising the REMS to remove the requirement for patients to abstain from alcohol entirely for 24 hours before each dose. The updated language instead instructs patients not to drink alcohol on the same day they take Addyi, specifically within the two-hour window before and after the bedtime dose. The prescriber and pharmacy certification requirements remained in place.

This modification generated debate. Some clinicians argued the change was clinically meaningful and reduced a burdensome restriction that had suppressed prescribing. Others noted that the original data from the first alcohol-interaction study still showed significant hemodynamic effects even with modest alcohol quantities, and that any loosening of the warning could increase syncope events in real-world use.

The HealthRX clinical team uses a three-question pre-prescription screen for Addyi that differs from the REMS checklist in one respect: we ask about binge-drinking history over the prior 90 days rather than simply asking whether the patient "drinks alcohol." Patients who report more than one episode of consuming four or more drinks in a single sitting in the prior 90 days are not offered flibanserin as a first-line option, even if they affirm willingness to comply with the label's alcohol restriction.

Post-Market Safety: What Has Surveillance Found?

The FDA's Adverse Event Reporting System (FAERS) database includes post-market syncope and hypotension reports for flibanserin since 2015. A 2020 pharmacovigilance analysis in Drug Safety identified disproportionate reporting of syncope and loss of consciousness in FAERS for flibanserin compared with other CNS-active drugs, with a reporting odds ratio of 6.8 (95% CI 4.3 to 10.9) for the syncope signal [2]. The analysis noted that most reported syncope events involved concomitant alcohol or a CNS depressant, consistent with the known mechanism.

Driving and Cognitive Impairment Signals

One concern raised during the 2013 advisory cycle and again during the 2015 committee meeting was potential next-morning impairment affecting driving. A dedicated driving simulation study published in the Journal of Clinical Pharmacology in 2016 found that standard driving performance metrics were not significantly different from placebo at 8 hours post-dose in well-rested subjects [3]. The label therefore does not prohibit driving, but it does caution patients to be aware of how the drug affects them before driving or operating heavy machinery.

Pregnancy and Lactation Data

The label carries a Pregnancy Category designation noting that animal studies showed fetal harm at doses well above the human therapeutic dose, and no adequate human pregnancy data exist. Women planning pregnancy should discontinue flibanserin. No data on excretion into human breast milk are available, and breastfeeding is not recommended during treatment.

Flibanserin Compared with Other HSDD Pharmacotherapy

Bremelanotide (Vyleesi): The Second Approval

In June 2019, the FDA approved bremelanotide (Vyleesi) as the second drug indicated for HSDD in premenopausal women. Bremelanotide is a melanocortin receptor agonist administered as a subcutaneous injection 45 minutes before anticipated sexual activity, a fundamentally different use pattern from flibanserin's daily oral dosing. The FDA approval announcement for bremelanotide noted nausea (40 percent of subjects), flushing, and transient increases in blood pressure as primary concerns.

Clinicians now have two approved options with different mechanisms, administration routes, and safety profiles. Flibanserin suits patients seeking a continuous daily treatment. Bremelanotide suits patients who prefer situational, on-demand dosing and who can tolerate the injection and nausea risk.

Off-Label Testosterone

Testosterone therapy, typically compounded topical testosterone at doses of 0.5 to 1 mg per day, is used off-label for HSDD by many clinicians. The Endocrine Society's 2019 guideline on androgen therapy published in the Journal of Clinical Endocrinology and Metabolism states: "We recommend testosterone therapy for postmenopausal women with HSDD" but explicitly notes insufficient evidence to recommend it for premenopausal women [4]. Neither formulation approved for men nor any compounded testosterone product carries an FDA indication for female HSDD.

Who Is an Appropriate Candidate for Addyi?

The label specifies premenopausal women with acquired, generalized HSDD. Clinicians should rule out:

• A relationship problem as the primary driver of low desire
• An underlying mood or anxiety disorder that, when treated, may restore desire
• Medications causing HSDD, most often SSRIs and SNRIs, as the underlying cause
• Hormonal contraceptive effects on libido that could be addressed by a method switch

A structured pre-prescription work-up matters here. The Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale-Revised (FSDS-R) are the validated instruments used in the key trials. Scores on the FSDS-R above 11 indicate clinically significant distress, the threshold used in BEGONIA and the other Phase 3 studies.

Patients taking fluoxetine, paroxetine, or strong azole antifungals cannot safely use flibanserin. The drug interaction burden in this category is not trivial: CYP3A4 inhibitors that are commonly prescribed include grapefruit juice (a moderate inhibitor), hormonal contraceptives containing ethinyl estradiol (weak inhibitor), and over-the-counter supplements such as ginkgo biloba, which has CYP3A4 inhibitory properties at high doses.

Addyi's Market Performance and Access Issues

Despite being the first approved drug in its class, Addyi's commercial uptake has been modest. Prescription data from IQVIA (formerly IMS Health) indicated that fewer than 20,000 prescriptions per month were filled in the first year after launch, a fraction of the utilization seen with erectile dysfunction drugs in their first years. Analysts attributed this to the strict REMS certification burden on prescribers and pharmacies, the alcohol contraindication, insurance coverage limitations, and a retail price of approximately $800 to $900 per month before coupons.

Generic flibanserin is not yet available in the United States as of early 2025.

FDA Oversight and Ongoing Surveillance Commitments

As part of the 2015 approval, Sprout Pharmaceuticals agreed to several post-market study commitments. These included a dedicated study of the drug-drug interaction with combined hormonal contraceptives, a long-term cardiovascular safety assessment, and a study characterizing the pharmacokinetics in women over age 65. Results from some of these commitments have been submitted to the FDA and are reflected in labeling updates published through the FDA's Drugs@FDA portal.

The FDA Sentinel System, which uses linked insurance claims and pharmacy records across millions of patients, continues to monitor flibanserin for syncope, motor vehicle accident, and CNS-injury signals in the post-market setting. No safety label update beyond the 2019 REMS modification has been issued as of the last review of Drugs@FDA NDA 022526.